In the last trading session, 1.09 million Vir Biotechnology Inc (NASDAQ:VIR) shares changed hands as the company’s beta touched 0.55. With the company’s per share price at $9.25 changed hands at -$0.62 or -6.28% during last session, the market valuation stood at $1.27B. VIR’s last price was a discount, traded about -41.51% off its 52-week high of $13.09. The share price had its 52-week low at $7.12, which suggests the last value was 23.03% up since then. When we look at Vir Biotechnology Inc’s average trading volume, we note the 10-day average is 1.76 million shares, with the 3-month average coming to 905.32K.
Analysts gave the Vir Biotechnology Inc (VIR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.78. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended VIR as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Vir Biotechnology Inc’s EPS for the current quarter is expected to be -0.86.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Vir Biotechnology Inc (NASDAQ:VIR) trade information
Instantly VIR was in red as seen at the end of in last trading. With action -4.05%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -8.05%, with the 5-day performance at -4.05% in the red. However, in the 30-day time frame, Vir Biotechnology Inc (NASDAQ:VIR) is 20.60% up. Looking at the short shares, we see there were 5.55 million shares sold at short interest cover period of 6.87 days.
The consensus price target for the stock as assigned by Wall Street analysts is 28.19, meaning bulls need an upside of 67.19% from its current market value. According to analyst projections, VIR’s forecast low is 15 with 35 as the target high. To hit the forecast high, the stock’s price needs a -278.38% plunge from its current level, while the stock would need to soar -62.16% for it to hit the projected low.
Vir Biotechnology Inc (VIR) estimates and forecasts
Data shows that the Vir Biotechnology Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -8.23% over the past 6 months, a 15.90% in annual growth rate that is considerably lower than the industry average of 17.10%. Year-over-year growth is forecast to reach -20.30% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 8.14M. 3 analysts are of the opinion that Vir Biotechnology Inc’s revenue for the current quarter will be 18.21M. The company’s revenue for the corresponding quarters a year ago was 16.79M and 11.71M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -51.50%. The estimates for the next quarter sales put growth at 55.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -34.12%. The 2024 estimates are for Vir Biotechnology Inc earnings to increase by 16.32%, but the outlook for the next 5-year period is at 7.00% per year.
VIR Dividends
Vir Biotechnology Inc is expected to release its next quarterly earnings report in December.
Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.85% of Vir Biotechnology Inc shares while 74.00% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 83.95%. There are 74.00% institutions holding the Vir Biotechnology Inc stock share, with SB INVESTMENT ADVISERS (UK) LTD the top institutional holder. As of 2024-06-30, the company held 12.3329% of the shares, roughly 16.68 million VIR shares worth $148.49 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 12.1482% or 16.43 million shares worth $146.26 million as of 2024-06-30.
